Woodward Kristine E, Murthy Prashanth, Mineyko Aleksandra, Mohammad Khorshid, Esser Michael J
Department of Pediatrics, Section of Neurology, University of Calgary, Cumming School of Medicine, 9978Alberta Children's Hospital, Calgary, Canada.
Department of Neurosciences, University of Calgary, Cumming School of Medicine, 9978Alberta Children's Hospital, Calgary, Canada.
J Child Neurol. 2023 Feb;38(1-2):16-24. doi: 10.1177/08830738221147805. Epub 2023 Jan 10.
Neonatal hypoxic-ischemic encephalopathy is a clinical phenomenon that often results from perinatal asphyxia. To mitigate secondary neurologic injury, prompt initial assessment and diagnosis is needed to identify patients eligible for therapeutic hypothermia. However, occasionally neonates present with a clinical picture of hypoxic-ischemic encephalopathy without significant risk factors for perinatal asphyxia. We hypothesized that in patients with genetic abnormalities, the clinical manifestation of those abnormalities may overlap with hypoxic-ischemic encephalopathy criteria, potentially contributing to a causal misattribution. We reviewed 210 charts of infants meeting local protocol criteria for moderate to severe hypoxic-ischemic encephalopathy in neonatal intensive care units in Calgary, Alberta. All patients that met criteria for therapeutic hypothermia were eligible for the study. Data were collected surrounding pregnancy and birth histories, as well as any available genetic or metabolic testing including microarray, gene panels, whole-exome sequencing, and newborn metabolic screens. Twenty-eight patients had genetic testing such as microarray, whole-exome sequencing, or a gene panel, because of clinical suspicion. Ten of 28 patients had genetic mutations, including , pyruvate dehydrogenase, , , , , , , , and . All patients lacked significant risk factors to support a moderate to severe hypoxic-ischemic encephalopathy diagnosis. Treatment was changed in 2 patients because of confirmed genetic etiology. This study demonstrates the importance of identifying genetic comorbidities as potential contributors to a hypoxic-ischemic encephalopathy phenotype in neonates. Early identification of clinical factors that support an alternate diagnosis should be considered when the patient's clinical picture is not typical of hypoxic-ischemic encephalopathy and could aid in both treatment decisions and outcome prognostication.
新生儿缺氧缺血性脑病是一种常由围产期窒息导致的临床现象。为减轻继发性神经损伤,需要进行迅速的初始评估和诊断,以确定适合接受治疗性低温的患者。然而,偶尔会有新生儿表现出缺氧缺血性脑病的临床症状,却没有围产期窒息的显著风险因素。我们推测,在患有基因异常的患者中,这些异常的临床表现可能与缺氧缺血性脑病的标准重叠,从而可能导致因果关系的错误归因。我们回顾了艾伯塔省卡尔加里市新生儿重症监护病房中符合当地中度至重度缺氧缺血性脑病方案标准的210名婴儿的病历。所有符合治疗性低温标准的患者均有资格参与该研究。收集了有关妊娠和出生史的数据,以及任何可用的基因或代谢检测结果,包括微阵列、基因panel、全外显子测序和新生儿代谢筛查。由于临床怀疑,28名患者进行了基因检测,如微阵列、全外显子测序或基因panel。28名患者中有10名存在基因突变,包括丙酮酸脱氢酶、、、、、、、和。所有患者均缺乏支持中度至重度缺氧缺血性脑病诊断的显著风险因素。2名患者因确诊的基因病因改变了治疗方案。这项研究证明了识别基因共病作为新生儿缺氧缺血性脑病表型潜在促成因素的重要性。当患者的临床表现不符合缺氧缺血性脑病的典型特征时,应考虑尽早识别支持其他诊断的临床因素,这有助于治疗决策和预后判断。